Dr. D. James Morré, PhD – Co-Founder and Director of Research:
Discovery of the ENOX2 Serum Cancer Marker
The ENOX proteins comprise a family of cell surface enzymes that are essential to the growth phase of cell proliferation. One member of this family, ENOX2, is universally produced by cancer cells after malignant transformation due to differential splicing of the ENOX2 messenger RNA. The activity of ENOX2 is critical for the proliferation of cancer cells. In contrast, ENOX2 is completely absent from normal cells and tissues. Therefore, the ENOX2 protein represents both a universal diagnostic marker for cancer presence and a therapeutic target.
Dr. David Taggart, PhD – Director of Proteomics Research:
Clinical Applications of the ENOX2 Serum Cancer Marker
The ENOX2 cancer marker is produced by cancer cells due to alternative splicing of the ENOX2 messenger RNA. This differential splicing also results in the production of tissue-specific forms of the ENOX2 protein, which are subsequently shed into circulation. These tissue-specific forms of ENOX2 in serum can be both separated and detected. Currently, the patterns of ENOX2 protein expression of 26 cancers from 20 tissues of origin have been determined and cataloged. Consequently, the ENOX2 serum cancer marker has utility for both the confirmation of cancer presence and assisting in identification of the tissue of cancer origin.
To order ONCOBLOT testing, call Rupert Case Management Inc. at
647 350 5500